421 related articles for article (PubMed ID: 9179871)
1. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
3. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
4. Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle.
Ekblad E; Sundler F
Eur J Pharmacol; 1997 Sep; 334(1):61-6. PubMed ID: 9346329
[TBL] [Abstract][Full Text] [Related]
5. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
6. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
9. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
[TBL] [Abstract][Full Text] [Related]
11. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
[TBL] [Abstract][Full Text] [Related]
12. Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion.
Nogi H; Hashimoto H; Hagihara N; Shimada S; Yamamoto K; Matsuda T; Tohyama M; Baba A
Neurosci Lett; 1997 May; 227(1):37-40. PubMed ID: 9178853
[TBL] [Abstract][Full Text] [Related]
13. Facilitatory effects of pituitary adenylate cyclase activating polypeptide (PACAP) on neurons in the magnocellular portion of the rat hypothalamic paraventricular nucleus (PVN) in vitro.
Uchimura D; Katafuchi T; Hori T; Yanaihara N
J Neuroendocrinol; 1996 Feb; 8(2):137-43. PubMed ID: 8868261
[TBL] [Abstract][Full Text] [Related]
14. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
15. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
16. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.
Dickinson T; Mitchell R; Robberecht P; Fleetwood-Walker SM
Neuropharmacology; 1999 Jan; 38(1):167-80. PubMed ID: 10193908
[TBL] [Abstract][Full Text] [Related]
17. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.
Inagaki N; Kuromi H; Seino S
Ann N Y Acad Sci; 1996 Dec; 805():44-51; discussion 52-3. PubMed ID: 8993392
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal polypeptide- and pituitary adenylate cyclase activating polypeptide-mediated control of catecholamine release from chromaffin tissue in the rainbow trout, Oncorhynchus mykiss.
Montpetit CJ; Perry SF
J Endocrinol; 2000 Sep; 166(3):705-14. PubMed ID: 10974664
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
20. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
